Copyright © 2011 Eric P. Davidson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. L. J. Coppey, E. P. Davidson, J. A. Dunlap, D. D. Lund, and M. A. Yorek, “Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve,” Experimental Diabesity Research, vol. 1, no. 2, pp. 131–143, 2000. View at Google Scholar · View at Scopus
2. L. J. Coppey, J. S. Gellett, E. P. Davidson, J. A. Dunlap, and M. A. Yorek, “Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatis nerve,” International Journal of Experimental Diabetes Research, vol. 3, no. 1, pp. 21–36, 2002. View at Publisher · View at Google Scholar · View at Scopus
3. J. A. Davidson, “Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors,” Mayo Clinic Proceedings, vol. 85, no. 12, pp. S27–S37, 2010. View at Publisher · View at Google Scholar · View at Scopus
4. B. Lee, L. Shi, D. B. Kassel, T. Asakawa, K. Takeuchi, and R. J. Christopher, “Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys,” European Journal of Pharmacology, vol. 589, no. 1–3, pp. 306–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
5. J. J. Neumiller, L. Wood, and R. K. Campbell, “Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus,” Pharmacotherapy, vol. 30, no. 5, pp. 463–484, 2010. View at Publisher · View at Google Scholar · View at Scopus
6. S. Lam and M. Saad, “Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes,” Cardiology in Review, vol. 18, no. 4, pp. 213–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
7. E. Matteucci and O. Giampietro, “Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme,” Current Medicinal Chemistry, vol. 16, no. 23, pp. 2943–2951, 2009. View at Publisher · View at Google Scholar · View at Scopus
8. C. F. Deacon, M. Toft-Nielsen, L. Pridal, B. Willms, and J. J. Holst, “Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects,” Diabetes, vol. 44, no. 9, pp. 1126–1131, 1995. View at Google Scholar · View at Scopus
9. T. J. Kieffer, C. H. S. McIntosh, and R. A. Pederson, “Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV,” Endocrinology, vol. 136, no. 8, pp. 3585–3596, 1995. View at Google Scholar · View at Scopus
10. J. Mu, A. Petrov, G. J. Eiermann et al., “Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes,” European Journal of Pharmacology, vol. 623, no. 1–3, pp. 148–154, 2009. View at Publisher · View at Google Scholar · View at Scopus
11. L. Ferreira, E. Teixeira-De-Lemos, F. Pinto et al., “Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat),” Mediators of Inflammation, vol. 2010, Article ID 592760, 11 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
12. C. L. Oltman, E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt, D. D. Lund, and M. A. Yorek, “Attenuation of vascular/neural dysfunction in zucker rats treated with enalapril or rosuvastatin,” Obesity, vol. 16, no. 1, pp. 82–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
13. C. L. Oltman, L. J. Coppey, J. S. Gellett, E. P. Davidson, D. D. Lund, and M. A. Yorek, “Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats,” American Journal of Physiology, vol. 289, no. 1, pp. E113–E122, 2005. View at Publisher · View at Google Scholar · View at Scopus
14. I. G. Obrosova, F. Li, O. I. Abatan et al., “Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy,” Diabetes, vol. 53, no. 3, pp. 711–720, 2004. View at Publisher · View at Google Scholar · View at Scopus
15. K. K. Beiswenger, N. A. Calcutt, and A. P. Mizisin, “Epidermal nerve fiber quantification in the assessment of diabetic neuropathy,” Acta Histochemica, vol. 110, no. 5, pp. 351–362, 2008. View at Publisher · View at Google Scholar · View at Scopus
16. E. P. Davidson, L. J. Coppey, N. A. Calcutt, C. L. Oltman, and M. A. Yorek, “Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 4, pp. 306–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
17. L. J. Coppey, J. S. Gellett, E. P. Davidson, J. A. Dunlap, D. D. Lund, and M. A. Yorek, “Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve,” Diabetes, vol. 50, no. 8, pp. 1927–1937, 2001. View at Google Scholar · View at Scopus
18. L. J. Coppey, E. P. Davidson, T. W. Rinehart et al., “ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats,” Diabetes, vol. 55, no. 2, pp. 341–348, 2006. View at Publisher · View at Google Scholar · View at Scopus
19. M. A. Yorek, L. J. Coppey, J. S. Gellett, and E. P. Davidson, “Sensory nerve innervation of epineurial arterioles of the sciatic nerve containing calcitonin gene-related peptide: effect of streptozotocin-induced diabetes,” Experimental Diabesity Research, vol. 5, no. 3, pp. 187–193, 2004. View at Publisher · View at Google Scholar · View at Scopus
20. E. P. Davidson, T. L. Kleinschmidt, C. L. Oltman, D. D. Lund, and M. A. Yorek, “Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: effect on vascular and neural disease,” Diabetes, vol. 56, no. 2, pp. 355–362, 2007. View at Publisher · View at Google Scholar · View at Scopus
21. C. L. Oltman, E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt, B. Dake, and M. A. Yorek, “Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats,” European Journal of Pharmacology, vol. 650, no. 2-3, pp. 556–562, 2011. View at Publisher · View at Google Scholar
22. E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt, C. L. Oltman, and M. A. Yorek, “Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688,” Experimental Diabetes Research, vol. 2009, p. 912327, 2009. View at Google Scholar · View at Scopus
23. M. A. Yorek, “The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy,” Current Drug Targets, vol. 9, no. 1, pp. 77–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
24. J. Doupis and A. Veves, “DPP4 inhibitors: a new approach in diabetes treatment.,” Advances in Therapy, vol. 25, no. 7, pp. 627–643, 2008. View at Publisher · View at Google Scholar · View at Scopus
25. B. Ahrén, “Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes,” Expert Opinion on Emerging Drugs, vol. 13, no. 4, pp. 593–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
26. A. M. Lambeir, S. Scharpé, and I. De Meester, “DPP4 inhibitors for diabetes-What next?” Biochemical Pharmacology, vol. 76, no. 12, pp. 1637–1643, 2008. View at Publisher · View at Google Scholar · View at Scopus
27. E. J. Verspohl, “Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors,” Pharmacology and Therapeutics, vol. 124, no. 1, pp. 113–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
28. Y. Moritoh, K. Takeuchi, T. Asakawa, O. Kataoka, and H. Odaka, “Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice,” European Journal of Pharmacology, vol. 588, no. 2-3, pp. 325–332, 2008. View at Publisher · View at Google Scholar · View at Scopus
29. Y. Moritoh, K. Takeuchi, and M. Hazama, “Chronic administration of voglibose, an α-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 329, no. 2, pp. 669–676, 2009. View at Publisher · View at Google Scholar · View at Scopus
30. A. Tahara, A. Matsuyama-Yokono, R. Nakano, Y. Someya, M. Hayakawa, and M. Shibasaki, “Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors,” Pharmacological Reports, vol. 61, no. 5, pp. 899–908, 2009. View at Google Scholar · View at Scopus
31. A. Matsuyama-Yokono, A. Tahara, R. Nakano, Y. Someya, M. Hayakawa, and M. Shibasaki, “Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA1c level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 379, no. 2, pp. 191–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
32. T. J. Wiese, W. L. Lowe Jr., and M. A. Yorek, “Regulation of the Na+/myo-inositol cotransporter mRNA levels in streptozotocin-induced diabetic rats and by hyperglycemia in cultured cells,” International Journal of Diabetes, vol. 4, pp. 107–121, 1996. View at Google Scholar
33. E. Davidson, L. Coppey, B. Lu et al., “The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy,” Experimental Diabetes Research, vol. 2009, p. 431980, 2009. View at Google Scholar · View at Scopus
34. K. Sugimoto, K. Kojima, M. Baba, and M. Yasujima, “Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats,” Journal of Hypertension, vol. 29, no. 7, pp. 1337–1346, 2011. View at Publisher · View at Google Scholar
35. I. G. Obrosova, W. Xu, V. V. Lyzogubov et al., “PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy,” Free Radical Biology and Medicine, vol. 44, no. 6, pp. 972–981, 2008. View at Publisher · View at Google Scholar · View at Scopus
36. V. R. Drel, P. Pacher, I. Vareniuk et al., “A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice,” European Journal of Pharmacology, vol. 569, no. 1-2, pp. 48–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
37. R. Stavniichuk, V. R. Drel, H. Shevalye et al., “Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation,” Experimental Neurology, vol. 230, no. 1, pp. 106–113, 2011. View at Publisher · View at Google Scholar
38. K. K. Beiswenger, N. A. Calcutt, and A. P. Mizisin, “Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice,” Neuroscience Letters, vol. 442, no. 3, pp. 267–272, 2008. View at Publisher · View at Google Scholar · View at Scopus
39. H. Y. Jin, W. J. Liu, J. H. Park, H. S. Baek, and T. S. Park, “Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats,” Archives of Medical Research, vol. 40, no. 7, pp. 536–544, 2009. View at Publisher · View at Google Scholar · View at Scopus
40. M. A. Nauck and A. El-Ouaghlidi, “The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1,” Diabetologia, vol. 48, no. 4, pp. 608–611, 2005. View at Publisher · View at Google Scholar · View at Scopus